OXT-OXTR pathway active in posterior retina

Article

The posterior retina is a site of oxytocin (OXT) activation of the oxytocin receptor (OXTR), according to a study published online.

The posterior retina is a site of oxytocin (OXT) activation of the oxytocin receptor (OXTR), which may serve as a paracrine signalling pathway contributing to communication between the retinal pigment epithelium and the cone photoreceptor, according to a study published online in Investigative Ophthalmology and Visual Science.

Researchers from the University of Wisconsin (USA), used immunohistochemistry using cell specific markers to localize OXT within a rhesus retina, and reverse transcription polymerase chain reaction (RT-PCR) and immunohistochemistry to assess the expression of OXTR in both rhesus and human retinas.

To determine the expression of OXTR in cultured human foetal retinal pigment epithelium (hfRPE) cells, the researchers used single-cell RT-PCR and Western blot analyses. To assess transient mobilization of intracellular Ca2+ ([Ca2+]i), the hfRPE cells were loaded with Fura-2-acetoxymethyl ester and studied by ratiometric Ca2+ imaging.

They found that, in the rhesus retina, OXT was expressed in the cone photoreceptor extracellular matrix, and OXTR mRNA and protein were expressed in both the human and rhesus retinal pigment epithelium. In the cultured hfRPE cells, OXTR mRNA and protein expression were observed, and a transient increase of [Ca2+]i was induced by exposure of these cells to 100 nM OXT.

The researchers concluded that OXT and OXTR are present in the posterior retina and OXT causes an increase in hfRPE [Ca2+]i , suggesting that the retina is an active site of the OXT-OXTR signaling pathway.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.